Advertisement

Archives of Osteoporosis

, 10:30 | Cite as

Use of anti-osteoporotic drugs in central Norway after a forearm fracture

  • Mari HoffEmail author
  • Svetlana Skurtveit
  • Haakon E. Meyer
  • Arnulf Langhammer
  • Anne Johanne Søgaard
  • Unni Syversen
  • Bo Abrahamsen
  • Berit Schei
Original Article

Abstract

Summary

Use of anti-osteoporotic drugs (AOD) the first year after a forearm fracture in central Norway was low in the period 2005–2012. Women with fractures used more AOD compared to the general population only in 2006, 2007, and 2011. Female gender, age ≥ 60 years, use of glucocorticosteroids, or ≥ 4 different drugs were associated with AOD use.

Purpose

The primary aim of this study was to examine time trends in prevalence and incidence of AOD use the first year after a forearm fracture from 2005–2012. Further, secondary aims were to investigate if gender, the number of drugs used before fracture, or use of glucocorticoids influenced the prescription of AOD, and to examine adherence to AOD.

Methods

Data is from the fracture registry in Nord-Trøndelag and the Norwegian Prescription database, including women (N = 1434) and men (N = 513) 40–84 years with their first forearm fracture between 2005 and 2012. AOD were defined as bisphosphonates, teriparatide, denosumab, and raloxifene. Prevalence and incidence were calculated, and prevalent use among women with forearm fracture was compared with the population in Nord-Trøndelag and Norway. Age-adjusted Poisson regression analyses for time trends and odds ratio for treatment with AOD was estimated. Adherence was defined as medication possession ratio ≥ 80 %.

Results

The first year after the fracture, 11.2 % of the women and 2.7 % of the men were prevalent users, while 5.1 % and 1.2 %, respectively, were incident users of AOD. Bisphosphonates comprised 98.8 %. AOD use among women with fractures was significantly higher compared to the general population in Nord-Trøndelag only in 2006, 2007, and 2011. There was a trend towards a decline in AOD use among women with fractures from 2005 to 2012 (coefficient −0.05, p = 0.15). Female gender, age ≥ 60 years, use of glucocorticosteroids, or ≥ 4 different drugs the last year before fracture were associated with AOD use.

In women, 54.8 % were adherent during 3 years after fracture.

Conclusions

The use of AOD after a forearm fracture was low. An increased focus on osteoporosis in fracture patients is needed for secondary fracture prevention.

Keywords

Forearm fracture Osteoporosis Anti-osteoporotic drugs Bisphosphonates Glucocorticoids 

Notes

Acknowledgments

The Fracture Register in Nord-Trøndelag was established by The Nord-Trøndelag Hospital Trust. The work was supported by the Liaison Committee between the Central Norway Regional Health Authority (RHA) and the Norwegian University of Science and Technology (NTNU).

Conflicts of interests

BA has received research grants from or served as a principal investigator in studies funded by Novartis, Nycomed/Takeda, NPS Pharmaceuticals, and Amgen. US has received research grants from or served as a principal investigator in studies conducted by Amgen, Eli Lilly, Novartis, Merck, and Wyeth pharmaceuticals. MH, SS, HM, AJS, AL, and BS have no disclosures.

References

  1. 1.
    Singer A, Exuzides A, Spangler L, O'Malley C, Colby C, Johnston K, Agodoa I, Baker J, Kagan R (2015) Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States. Mayo Clin Proc 90(1):53–62. doi: 10.1016/j.mayocp.2014.09.011 PubMedCrossRefGoogle Scholar
  2. 2.
    Kanis JA, Oden A, McCloskey EV, Johansson H, Wahl DA, Cooper C, on behalf of the IOFWGoE, Quality of L (2012) A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int 23(9):2239–2256. doi: 10.1007/s00198-012-1964-3 PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    (1993) Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94 (6):646–650Google Scholar
  4. 4.
    Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N (1994) The diagnosis of osteoporosis. J Bone Miner Res 9(8):1137–1141. doi: 10.1002/jbmr.5650090802 PubMedCrossRefGoogle Scholar
  5. 5.
    Cuddihy MT, Gabriel SE, Crowson CS, O'Fallon WM, Melton LJ 3rd (1999) Forearm fractures as predictors of subsequent osteoporotic fractures. Osteoporos Int 9(6):469–475PubMedCrossRefGoogle Scholar
  6. 6.
    Freedman KB, Kaplan FS, Bilker WB, Strom BL, Lowe RA (2000) Treatment of osteoporosis: are physicians missing an opportunity? J Bone Joint Surg Am 82-A(8):1063–1070PubMedGoogle Scholar
  7. 7.
    Cuddihy MT, Gabriel SE, Crowson CS, Atkinson EJ, Tabini C, O'Fallon WM, Melton LJ 3rd (2002) Osteoporosis intervention following distal forearm fractures: a missed opportunity? Arch Intern Med 162(4):421–426PubMedCrossRefGoogle Scholar
  8. 8.
    Hansen L, Petersen KD, Eriksen SA, Langdahl BL, Eiken PA, Brixen K, Abrahamsen B, Jensen JE, Harslof T, Vestergaard P (2015) Subsequent fracture rates in a nationwide population-based cohort study with a 10-year perspective. Osteoporos Int 26(2):513–519. doi: 10.1007/s00198-014-2875-2 PubMedCrossRefGoogle Scholar
  9. 9.
    Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, Eisman J, Fujiwara S, Garnero P, Kroger H, McCloskey EV, Mellstrom D, Melton LJ, Pols H, Reeve J, Silman A, Tenenhouse A (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35(2):375–382. doi: 10.1016/j.bone.2004.03.024 PubMedCrossRefGoogle Scholar
  10. 10.
    Devold HM, Sogaard AJ, Tverdal A, Falch JA, Furu K, Meyer HE (2013) Hip fracture and other predictors of anti-osteoporosis drug use in Norway. Osteoporos Int 24(4):1225–1233. doi: 10.1007/s00198-012-2063-1 PubMedCrossRefGoogle Scholar
  11. 11.
    Panneman MJ, Lips P, Sen SS, Herings RM (2004) Undertreatment with anti-osteoporotic drugs after hospitalization for fracture. Osteoporos Int 15(2):120–124. doi: 10.1007/s00198-003-1544-7 PubMedCrossRefGoogle Scholar
  12. 12.
    Erny F, Auvinet A, Chu Miow Lin D, Pioger A, Haguenoer K, Tauveron P, Jacquot F, Rusch E, Goupille P, Mulleman D (2015) Management of osteoporosis in women after forearm fracture: data from a French health insurance database. Joint Bone Spine 82(1):52–55. doi: 10.1016/j.jbspin.2014.07.007 PubMedCrossRefGoogle Scholar
  13. 13.
    Rud B, Greibe R, Hyldstrup L, Sorensen HA (2005) Does a distal forearm fracture lead to evaluation for osteoporosis? A retrospective cohort study in 147 Danish women. J Clin Densitom 8(1):18–24PubMedCrossRefGoogle Scholar
  14. 14.
    Roerholt C, Eiken P, Abrahamsen B (2009) Initiation of anti-osteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence. Osteoporos Int 20(2):299–307. doi: 10.1007/s00198-008-0651-x PubMedCrossRefGoogle Scholar
  15. 15.
    Gronskag AB, Forsmo S, Romundstad P, Langhammer A, Schei B (2010) Incidence and seasonal variation in hip fracture incidence among elderly women in Norway. The HUNT Study. Bone 46(5):1294–1298PubMedCrossRefGoogle Scholar
  16. 16.
    The Norwegian prescription database. The Norwegian Institute of Public Health. www.norpd.no.no
  17. 17.
    Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sorensen HT (2010) The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol 106(2):86–94. doi: 10.1111/j.1742-7843.2009.00494.x PubMedCrossRefGoogle Scholar
  18. 18.
    (2012) WHO collaborating centre for drug statistics methodology. Guidelines for ATC classification and DDD assignement. Norway: OsloGoogle Scholar
  19. 19.
    Regulations concerning food supplement in Norway (2004, revised 2014). https://lovdata.no/dokument/SF/forskrift/2004-05-20-755
  20. 20.
    Kanis JA, Oden A, Johansson H, Borgstrom F, Strom O, McCloskey E (2009) FRAX and its applications to clinical practice. Bone 44(5):734–743. doi: 10.1016/j.bone.2009.01.373 PubMedCrossRefGoogle Scholar
  21. 21.
  22. 22.
    Vollset SE (1993) Confidence intervals for a binomial proportion. Stat Med 12(9):809–824PubMedCrossRefGoogle Scholar
  23. 23.
    Krokstad S, Langhammer A, Hveem K, Holmen T, Midthjell K, Stene T, Bratberg G, Heggland J, Holmen J (2012) Cohort profile: the HUNT Study Norway. Int J Epidemiol. doi: 10.1093/ije/dys095 PubMedGoogle Scholar
  24. 24.
    Devold HM, Doung GM, Tverdal A, Furu K, Meyer HE, Falch JA, Sogaard AJ (2010) Prescription of anti-osteoporosis drugs during 2004-2007—a nationwide register study in Norway. Eur J Clin Pharmacol 66(3):299–306. doi: 10.1007/s00228-009-0746-0 PubMedCrossRefGoogle Scholar
  25. 25.
    Svedbom A, Hernlund E, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Kanis JA (2013) Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos 8(1–2):137. doi: 10.1007/s11657-013-0137-0 PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Balasubramanian A, Tosi LL, Lane JM, Dirschl DR, Ho PR, O'Malley CD (2014) Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009. J Bone Joint Surg Am 96(7):e52. doi: 10.2106/jbjs.l.01781 PubMedCrossRefGoogle Scholar
  27. 27.
    Diamantopoulos AP, Rohde G, Johnsrud I, Skoie IM, Hochberg M, Haugeberg G (2012) The epidemiology of low- and high-energy distal radius fracture in middle-aged and elderly men and women in Southern Norway. PLoS One 7(8):e43367. doi: 10.1371/journal.pone.0043367 PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Oyen J, Rohde GE, Hochberg M, Johnsen V, Haugeberg G (2010) Low-energy distal radius fractures in middle-aged and elderly women-seasonal variations, prevalence of osteoporosis, and associates with fractures. Osteoporos Int 1(7):1247–1255. doi: 10.1007/s00198-009-1065-0 CrossRefGoogle Scholar
  29. 29.
    Mallmin H, Ljunghall S (1994) Distal radius fracture is an early sign of general osteoporosis: bone mass measurements in a population-based study. Osteoporos Int 4(6):357–361PubMedCrossRefGoogle Scholar
  30. 30.
    Abrahamsen B, Jorgensen NR, Schwarz P (2015) Epidemiology of forearm fractures in adults in Denmark: national age- and gender-specific incidence rates, ratio of forearm to hip fractures, and extent of surgical fracture repair in inpatients and outpatients. Osteoporos Int 26(1):67–76. doi: 10.1007/s00198-014-2831-1 PubMedCrossRefGoogle Scholar
  31. 31.
    Oyen J, Diamantopoulos AP, Haugeberg G (2014) Mortality after distal radius fracture in men and women aged 50 years and older in southern Norway. PLoS One 9(11):e112098. doi: 10.1371/journal.pone.0112098 PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301(5):513–521. doi: 10.1001/jama.2009.50 PubMedCrossRefGoogle Scholar
  33. 33.
    Devold HM, Furu K, Skurtveit S, Tverdal A, Falch JA, Sogaard AJ (2012) Influence of socioeconomic factors on the adherence of alendronate treatment in incident users in Norway. Pharmacoepidemiol Drug Saf 21(3):297–304. doi: 10.1002/pds.2344 PubMedCrossRefGoogle Scholar
  34. 34.
    Crandall CJ, Newberry SJ, Diamant A, Lim YW, Gellad WF, Suttorp MJ, Motala A, Ewing B, Roth B, Shanman R, Timmer M, Shekelle PG (2012) Treatment to prevent fractures in men and women with low bone density or osteoporosis: update of a 2007 report. Rockville MDGoogle Scholar
  35. 35.
    Bultink IE, Baden M, Lems WF (2013) Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions. Expert Opin Pharmacother 14(2):185–197. doi: 10.1517/14656566.2013.761975 PubMedCrossRefGoogle Scholar
  36. 36.
    Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster DW, Ebeling PR, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Howe TS, van der Meulen MC, Weinstein RS, Whyte MP (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29(1):1–23. doi: 10.1002/jbmr.1998 PubMedCrossRefGoogle Scholar
  37. 37.
    Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, Al Dabagh R, Davison KS, Kendler DL, Sandor GK, Josse RG, Bhandari M, El Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 30(1):3–23. doi: 10.1002/jbmr.2405 PubMedCrossRefGoogle Scholar
  38. 38.
    Norwegian guidelines for prevention and treatment of osteoporosis and osteoporotic fractures. (2005). http://helsedirektoratet.no/publikasjoner/nasjonal-faglige-retningslinje-for-forebygging-og-behandling-av-osteoporose-og-osteoporotiske-brudd
  39. 39.
    Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, Rizzoli R (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19(4):399–428PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24(1):23–57. doi: 10.1007/s00198-012-2074-y PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288(3):321–333PubMedCrossRefGoogle Scholar
  42. 42.
    Schierbeck LL, Rejnmark L, Tofteng CL, Stilgren L, Eiken P, Mosekilde L, Kober L, Jensen JE (2012) Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 345:e6409. doi: 10.1136/bmj.e6409 PubMedCrossRefGoogle Scholar
  43. 43.
    Hodis HN, Mack WJ (2011) A “window of opportunity:” the reduction of coronary heart disease and total mortality with menopausal therapies is age- and time-dependent. Brain Res 1379:244–252. doi: 10.1016/j.brainres.2010.10.076 PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Lekamwasam S, Adachi JD, Agnusdei D, Bilezikian J, Boonen S, Borgstrom F, Cooper C, Diez Perez A, Eastell R, Hofbauer LC, Kanis JA, Langdahl BL, Lesnyak O, Lorenc R, McCloskey E, Messina OD, Napoli N, Obermayer-Pietsch B, Ralston SH, Sambrook PN, Silverman S, Sosa M, Stepan J, Suppan G, Wahl DA, Compston JE (2012) A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int 23(9):2257–2276. doi: 10.1007/s00198-012-1958-1 PubMedCrossRefGoogle Scholar
  45. 45.
    Eisman JA, Bogoch ER, Dell R, Harrington JT, McKinney RE Jr, McLellan A, Mitchell PJ, Silverman S, Singleton R, Siris E (2012) Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention. J Bone Miner Res 27(10):2039–2046. doi: 10.1002/jbmr.1698 PubMedCrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2015

Authors and Affiliations

  • Mari Hoff
    • 1
    • 2
    Email author
  • Svetlana Skurtveit
    • 3
    • 4
  • Haakon E. Meyer
    • 3
    • 5
  • Arnulf Langhammer
    • 1
  • Anne Johanne Søgaard
    • 3
  • Unni Syversen
    • 6
    • 7
  • Bo Abrahamsen
    • 8
    • 9
  • Berit Schei
    • 1
    • 10
  1. 1.Department of Public Health and General PracticeNorwegian University of Science and TechnologyTrondheimNorway
  2. 2.Department of RheumatologySt Olavs HospitalTrondheimNorway
  3. 3.Division of EpidemiologyNorwegian Institute of Public HealthOsloNorway
  4. 4.Norwegian Centre for Addiction ResearchUniversity of OsloOsloNorway
  5. 5.Institute of Health and SocietyUniversity of OsloOsloNorway
  6. 6.Department of EndocrinologySt. Olavs HospitalTrondheimNorway
  7. 7.Institute of Cancer Research and Molecular MedicineNorwegian University of Science and TechnologyTrondheimNorway
  8. 8.Research Centre for Ageing and Osteoporosis, Department of MedicineGlostrup HospitalGlostrupDenmark
  9. 9.Odense Patient Data Explorative Network, Institute of Clinical ResearchUniversity of Southern DenmarkOdenseDenmark
  10. 10.Department of GynecologySt Olavs HospitalTrondheimNorway

Personalised recommendations